Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amgen    AMGN

AMGEN (AMGN)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Amgen, Inc. : Amgen 1Q Profit Rises 5.2% On Broad Sales Growth

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/24/2012 | 10:40pm CEST

Amgen Inc.'s (AMGN) first-quarter earnings rose 5.2% as the biopharmaceutical company reported sales growth across many of its products, helping results beat expectations.

The company has been trying to bolster its research-and-development pipeline and grow sales of its bone-building drugs to help offset declining sales of its key anti-anemia drugs, which have slumped in recent years due to safety concerns and intensifying competition. Amgen recently completed $1.16 billion acquisition of Micromet Inc. (MITI), a deal expected to strengthen its cancer-drug research pipeline.

Amgen reported a profit of $1.18 billion, or $1.48 a share, up from $1.13 billion, or $1.20 a share, a year earlier. Excluding acquisition and restructuring-related expenses and other items, earnings were up at $1.61 from $1.34. Revenue increased 9.2% to $4.05 billion.

Analysts polled by Thomson Reuters most recently projected earnings of $1.45 on revenue of $3.93 billion.

Operating margin rose to 36.4% from 34.9%.

Combined sales of Neulasta and Neupogen, which are used to ward off infections undergoing cancer treatment, rose 9% to $1.34 billion.

The company has been counting on its new bone-building drugs, Xgeva and Prolia, to boost overall sales growth. Sales of Xgeva, a drug designed to prevent bone injuries in cancer patients, were up 14% to $153 million. Sales of Prolia, for osteoporosis in women, were up 9% to $153 million.

Shares of Amgen, which affirmed its 2012 guidance, were up 1% to $69.32 in recent after-hours trading.

-By Tess Stynes, Dow Jones Newswires; 212-416-2481; Tess.Stynes@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AMGEN
08/16 AMGEN : Repatha® (Evolocumab) Phase 3 Cognitive Function Study Results Published..
08/15 AMGEN : ex-dividend day
08/14 AMGEN : Dividend Coverage: This Biotech Drugmaker Pays Higher Dividend than the ..
08/10 AMGEN : Findings on Bone Resorption Reported by Researchers at Amgen (FGF21 Is N..
08/10 AMGEN : And Allergan Submit Biosimilar Biologics License Application For ABP 980..
08/10 RESEARCHERS AT AMGEN REPORT NEW DATA : Tools that bridge efficacy and...
08/10 NEW HYDROLASES DATA HAVE BEEN REPORT : Role of Epoxide...
08/03 AMGEN : Studies from Amgen in the Area of Neutral Amino Acids Described (Protein..
08/03 AMGEN : Researchers at Amgen Report New Data on Inflammatory Bowel Disease (Diff..
08/03 AMGEN : Findings from Amgen Has Provided New Data on Multiple Myeloma (Renal imp..
More news
News from SeekingAlpha
08/17 Amgen and Humana to research ways to improve patient outcomes and improve eff..
08/17 An Investment Guide To War With North Korea
08/15 20 Dividend Growth Stocks With Growth
08/14 Sand In My Shoes - Time To Regroup And Clarify
08/13 3 THINGS IN BIOTECH YOU SHOULD LEARN : August 13, 2017
Financials ($)
Sales 2017 22 849 M
EBIT 2017 11 791 M
Net income 2017 8 121 M
Finance 2017 8 718 M
Yield 2017 2,70%
P/E ratio 2017 15,17
P/E ratio 2018 15,06
EV / Sales 2017 4,98x
EV / Sales 2018 4,73x
Capitalization 122 447 M
Chart AMGEN
Duration : Period :
Amgen Technical Analysis Chart | AMGN | US0311621009 | 4-Traders
Technical analysis trends AMGEN
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 187 $
Spread / Average Target 12%
EPS Revisions
Managers
NameTitle
Robert A. Bradway Chairman & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
David W. Meline Executive VP, Chief Financial & Accounting Officer
Sean E. Harper Executive Vice President-Research & Development
Paul R. Eisenberg Chief Medical Officer & Senior VP-Global Medical
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN14.77%122 447
CELGENE CORPORATION10.22%99 812
GILEAD SCIENCES1.02%94 471
REGENERON PHARMACEUTICALS27.64%49 721
VERTEX PHARMACEUTICALS101.63%37 450
ACTELION23.81%30 636